MedTrace Logo

Characterization and Clinical Impact of the Gut Microbiota in Lymphoma

NCT06161896 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-08-09

No results posted yet for this study

Summary

The study is a prospective observational single-center cohort study which compare the gut microbiome of newly diagnosed Diffuse Large B-cell Lymphoma patients with the gut microbiome of healthy controls. Furthermore the impact of lymphoma treatment, immune phenotypes, cytokine profiles, metabolomics, inflammation, driver mutations, comorbidity, body composition and lifestyle on the microbiome is also investigated

Conditions

Interventions

DIAGNOSTIC_TEST

Stool samples

Analysis of microbiome, mutations, alterations in body composition and lifestyle

Sponsors & Collaborators

  • Zealand University Hospital

    collaborator OTHER

  • Herlev Hospital

    collaborator OTHER

  • Statens Serum Institut

    collaborator OTHER

  • Weill Medical College of Cornell University

    collaborator OTHER

  • Lars Møller Pedersen

    lead OTHER

Principal Investigators

  • Christiane Sophie Staxen, MSc · Zealand University Hospital - Roskilde

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-06
Primary Completion
2025-07-01
Completion
2026-07-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06161896 on ClinicalTrials.gov